The analysis weighs whether Viking can become the third company, after Lilly and Novo Nordisk, to win approval for a GLP-1 weight loss drug.
Recap by typeshit. Full story at Seeking Alpha.
The 52-year-old actor points to his early 4am workouts and discipline instead of weight loss shots. A celebrity opinion, not new data.
Metz says the drug improved her mobility enough to handle eight Broadway shows a week in "& Juliet". Her account, not a clinical claim.
A general piece on how GLP-1 drugs like Ozempic and Wegovy reshaped weight management in the US. Light on new details.
The broker says Laurus beat 2QFY27 estimates on EBITDA and profit, with its CDMO pipeline and peptide work driving the higher forecasts.
A repost points to a roundup of upcoming weight loss drugs, including ones that combine several hormone signals in a single treatment.
The endocrinologist explains that microdosing means taking far less than the doses recommended for treatment, and gives his view on the trend.
Loading…